Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
XORTX Therapeutics Inc
V.XRTX
Alternate Symbol(s):
XRTX
Healthcare
Biotechnology
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and...
XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (TSXV:XRTX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(243)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Oct 17, 2025 8:32am
Using technical analysis for this stock.
It is starting a new uptrend for shareholders today,so good luck to all of you guys
(19)
•••
Stocks2Go
X
Comment by
Stocks2Go
on May 16, 2025 2:42pm
RE:RE:Looks promising
Why do you say that? Outstanding share count under 4 million.
(203)
•••
Peggy123
X
Comment by
Peggy123
on Apr 17, 2025 9:28pm
RE:Looks promising
looks like a roolback coming lol
(471)
•••
Larder111
X
Post by
Larder111
on Nov 28, 2024 7:37pm
Looks promising
But not sure what the future holds.Picked up a few shares in hopes it will skyrocket..
(3)
•••
Stockwonder
X
Post by
Stockwonder
on Oct 09, 2024 7:12am
V.XRTX XORTX Initiates Precision Medicine Program
Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism Click here to read NEWS
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 08, 2024 7:30am
New Press Release - XORTX Welcomes New Member to the Board of Directors
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 08, 2024 7:00am
New Press Release - XORTX Announces Participation in Spring 2024 Investor Conferences
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 27, 2024 5:00am
New Press Release - XORTX Announces New Clinical Advisory Board Member
CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease (“ADPKD”),...
read article.
(21)
•••
StockHawk1
X
Post by
StockHawk1
on Mar 20, 2024 6:53pm
XRTX.v Unveils 2023 Milestones and 2024 Objectives
Yesterday, the pharmaceutical company XORTX Therapeutics Inc. (XRTX.v XRTX) shared its progress in 2023 and goals for 2024, mainly concerning its lead program aimed at treating a kidney disease called
...more
(2269)
•••
Betteryear2
X
Post by
Betteryear2
on Mar 19, 2024 10:07pm
XORTX Highlights Achievements of 2023
CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical
...more
(2)
•••
KOkidneydisease
X
Post by
KOkidneydisease
on Mar 19, 2024 1:12pm
use Bluestar BioAdvisors est. net sales to calc a CF NPV
XRx-008 Program Highlights – Independent Commercial Assessment In support of ongoing pharmaceutical partnership discussions, XORTX initiated an independent commercial assessment of the XRx-008
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 19, 2024 9:31am
New Press Release - XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial
(NewsDirect)New York, NY, March 19, 2024 – (Plato Data) -- In the realm of pharmaceutical innovation, XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), stands out for its significant achievements in 2023 and ambitious plans for 2024. XORTX, a late-stage clinical...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 19, 2024 5:00am
New Press Release - XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased...
read article.
(16)
•••
waves1
X
Post by
waves1
on Mar 15, 2024 4:58pm
New Patent for Treatment of Chronic Kidney Disease Submitted
Xorlo program which is in a Phase 2/3 trial in patients with stage 2-4 ADPKD. XRTX is continuing to scale up its supply and to conduct pre-launch activities in prep for a
...more
(21)
•••
StockHawk1
X
Post by
StockHawk1
on Mar 12, 2024 7:53pm
Health Tech: Breakthroughs in Polycystic Kidney Disease and
With a primary focus on polycystic kidney disease and diabetic kidney disease, XORTX Therapeutics (XRTX.v XRTX) is advancing clinical trials for potential groundbreaking therapies that could
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
Eshbal Signs Definitive Agreement to Acquire Majority Interest in NYC-Based Dare to Be Different Foods
Allied Critical Metals Confirms Ultra High-Grade Tungsten Zone at Borralha
Pinnacle Extends Gold-Silver Mineralized Horizon to Almost 500 Metres at Historic La Dura Mine
SALT: quietly powering industries, keeping roads safe, and even shaping the global economy
The first public copper company permitted to drill in Argentina’s newly opened Mendoza province